A Big Step Forward in Maternal Health Tech
A major deal just happened in the world of medical tech.
Laborie Medical Technologies is buying the JADA System from Organon. This system helps stop heavy bleeding after childbirth. The price tag? A whopping $465 million. That's a lot of money, but it's for a device that could save lives.
The JADA System: A Global Impact
- Already in over 2,000 hospitals in the U.S.
- Reached more than 20 countries
- FDA-approved, ensuring safety and effectiveness
Laborie is known for its work in urology, gastroenterology, and obstetrics. They're backed by Patricia Industries, a major player in finance.
Why This Acquisition Matters
Postpartum hemorrhage is a leading cause of maternal mortality. The JADA System helps control and treat this condition. By acquiring it, Laborie can expand its reach and impact in the obstetrics market.
"Childbirth is a profound moment in a woman's life. Every mother deserves support." — Chris Smith, President and CEO of Laborie
Critical Considerations
- Is this deal just about making money?
- Or is it truly about improving maternal health?
Behind every medical device and acquisition, there are real people and real lives at stake. This deal could make a big difference in maternal health. But it's up to Laborie to follow through on their promises.